Figure 2. Deficiency of TGFβ1 in activated CD4+ T cells and Treg cells enhances tumor-specific CTL responses (A and B) B16-OVA melanoma cells were injected into age-matched Tgfb1f/n and Tgfb1f/nTnfrsf4-cre mice and pulmonary metastatic nodules assessed 15–21 days later. The p value between two groups of pulmonary metastatic nodules is shown (Students t-test) *Depicts statistically significant difference. (C) Tgfb1f/n and Tgfb1f/nTnfrsf4-cre mice were challenged intraperitoneally with 1 × 106 El-4 tumor cells and the splenocytes were used as effectors against EL-4 targets at the indicated effector:target ratios. Chromium-51 (Cr-51) release assay 10 days after tumor challenge is shown. The p values between the two groups of number of metastatic nodules and percent Chromium-15 release are shown (Students t-test). *Depicts statistically significant difference.